Отчётный звонок Abbott Laboratories

… I said, I don't think is a bad, it's not a bad growth rate. It's just not as high as what we've seen before. And to your point on does it, you know, do these things keep you at this growth rate or does it accelerate? It drastically accelerates it, right? Any one of these markets that goes to reimburse an expansion or introduction of reimbursement, it dramatically accelerates the growth rate, as we've seen in the past, Larry. And you've accompanied this segment. It has significant impact. The challenge is not if these countries adopt it. The question is when and how to forecast it. And it's difficult for me to, you know, with a business of this size to try and pinpoint the exact reimbursement. But I can tell you we are very active in active discussions with very large markets to expand or introduce reimbursement. If I look ahead at some of the key reimbursement expansions that are coming, obviously the U.S. Type II is a huge opportunity. It's going to unlock, you know, around 10 million Medicare beneficiaries. It's going to accelerate commercial insurance coverage. This could be a multi-billion dollar opportunity. And it could happen in the fall. I just can't forecast it exactly when exactly it's going to happen. But when it does happen, it is going to definitely accelerate our sales. And we're planning and positioning ourselves to be in the best possible positions that relate to sales force, distribution, et cetera, to be able to capitalize on that opportunity. the international basal coverage expansion. I mean right now with all the work that we've done I'd say you've got France, you've got Japan, you've got Canada that have broadly adopted this. Those are three markets that are in the top ten international markets. There are another seven markets here that are pretty significant movers, some larger than these markets that we're having discussions and given the clinical data, given the The pressure from the societies and the patient populations, those are going to happen also. I just can't call it to the exact order. So these reimbursement opportunities, they're going to accelerate it. And until that happens, I guess I'd say, yeah, you're at this 8%, 9% growth rate, which on a $2 billion or approaching $10 billion business, that's not a bad business to be in. And I would say... and I would say we feel so strongly about this market and the ability for …

Sure. Yeah, we grew 13% in the first half. Our deal model that we put together to support the acquisition for 2026 had mid-teens. I feel confident that we'll achieve that. You know, the model called for second half being higher than first half and The integration is going very good, very well. We're not seeing any kind of issues or disruption. I'm just very impressed by the team there and their understanding of the market. And they've done a good job here at making sure that I understand all the different detailed kind of elements of how this market works and drives to your point of the care gap. CareGap volumes ramp in the second half, and that's what's going to help drive. It's not just that, but it's a contributing factor to the acceleration in the second half. CareGap programs really are, they help the health systems achieve their HEDIS credits, their CMR star ratings, and that focus from the healthcare systems for some reason tends to happen in the second half. So they're looking at their scores, they're looking at their ratings, and they're looking at ways of how they can ensure that they're achieving their targets. That seems to happen a lot in the second half. Do we have visibility? Yeah, we absolutely have visibility. We have, you know, the team is an incredible team there in terms of their market access team. They've got work to do, there's no doubt, but there's a lot of visibility to those programs and there's a lot of conversations that are happening with the health systems They're seeing a need to continue to push on earlier detection of Cologuard. So I feel good about the ramp-up of the care graph and the visibility to that. You mentioned price being an element there. So as we transition from Cologuard to Cologuard Plus, that's a little bit of a tailwind also. But I think there are a lot of key growth drivers here in the medium-long-term VJ, and they're all looking very good. If you look at the growth from Cologuard users, they're exceeding our expectations. So there's a certain forecast of how many new users we'll be able to bring in and the team of actually exceeding that target. The number of repeat users in Cologuard we talked about, the re-screen, that funnel is expanding and it is extremely reliable in terms of, since we have the names, people want to stay up to date with their screening. So that re-screen funnel is expanding and that's …